Skip to content

FARMACYZE

Active
Private limited companyfounded 2024active for 2 yearsMeiboomlaan 17, 8400 Oostende, BelgiumKBO/BCE: BE 1012.650.009
Summary

FARMACYZE has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €49,439 and a net result of €33,612. Its solvency ranks better than 78% of 22,773 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Overview

Official details

Source: KBO
Status
Active since 21-08-2024 Normal situation
Activity
Retail sale of pharmaceutical products NACE 47730and 3 others
Establishment unit
2.364.105.774 8400 Oostende, since 21-08-2024
Financial year end
31 December
Peppol
Reachable since 02-09-2024

Financial position

92 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.2%
Annual accounts 2025
Gross margin
€42,761
▲ 210%
Turnover
≈ €210,000
estimated
Profit
€33,612
▲ 210%
Equity
€49,439
▲ 212%
Total assets
€73,863
▲ 140%
Score breakdownraises riskFounded in 2024Size: total assets €73,863lowers riskLiquidity: current ratio 3.01, cash €59,386Equity €49,439 (66.9% of total assets)Show the evidence

Checked score

Score 2025
92 / 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 90% of micro companies in retail trade (NACE 47)
Financial strength · tick: 2024
Strong
Solvency 92+16
equity 66.9% of total assets
Liquidity 86+10
short-term debt 33.1% · cash 80.4%
Profitability 100=
return on assets 45.5%
Bankruptcy probability within 12 months
0.2% Very low
0%0.5%1.5%4%10%≥ 25%

About 2 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,272 companies, NACE 47, micro)
Last 24 months 09-2025: 0.5% 10-2025: 0.5%● unchanged vs 09-2025 11-2025: 0.5%● unchanged vs 10-2025 12-2025: 0.5%● unchanged vs 11-2025 01-2026: 0.5%● unchanged vs 12-2025 02-2026: 0.5%● unchanged vs 01-2026 03-2026: 0.5%● unchanged vs 02-2026 04-2026: 0.6%▲ +0.1 percentage points vs 03-2026 05-2026: 0.6%● unchanged vs 04-2026 06-2026: 0.6%● unchanged vs 05-2026 07-2026: 0.7%▲ +0.1 percentage points vs 06-2026highest value 08-2026: 0.2%▼ -0.5 percentage points vs 07-2026lowest value 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.2%● unchanged vs 09-2026 11-2026: 0.2%● unchanged vs 10-2026
Credit of up to €4,500 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 3.01 (2.06 in 2024), above the usual 1.5. Short-term debt is 33.1% and cash 80.4% of total assets. 33.1% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 78% of them on solvency, 88% on liquidity, 96% on profitability and 96% on growth.

The bankruptcy probability was computed on 02-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 3.01, cash €59,386
NBB · annual accounts
raises risk · Founded in 2024
Companies of this age fail more often than older ones. How much that weighs depends on the rest of the company's profile.
KBO
lowers risk · Equity €49,439 (66.9% of total assets)
NBB · annual accounts
raises risk · Size: total assets €73,863
Companies of this size fail more often. How much that weighs depends on the rest of the company's profile.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 02-07-2026, 29 days ahead of the deadline.
NBB · 2 filings
Deviation from the deadline
2025
29 days early
2024
21 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 2 accounts on average 25 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Where today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2024.
KBO publications

Key points

  • Positive: Higher net result than 81% of companies in retail tradesector median €5,084 · 22,754 companies €33,612 View

Recent changes

  1. · Gazette deed IncorporationStarting capital €5,000 · Appointment: WAUTERS Veronique Paula Hendrika (director)
All 3 events

Comparable companies

These companies have the same main activity as FARMACYZE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €63,200 and €74,800, founded in 2024.

CompanyTotal assetsGross margin
FARMACYZE Oostende€73,863€42,761
T.R.F. pharma Fléron€70,151€42,395
Charlotte Slabbinck Oudenburg€72,938€36,678
JDS Pharma La Louvière€63,805€40,475
ESPharma Anderlecht€74,825€51,161
ELKE SEGERS Grimbergen€63,242€37,590
FARMECHA SERVICES Bornem€72,929€53,286
Full comparison

Key facts about FARMACYZE

What is the company number of FARMACYZE?
The company number of FARMACYZE is 1012.650.009. The VAT number is the same number with BE in front: BE 1012.650.009.
Where is FARMACYZE based?
The registered office is at Meiboomlaan 17, 8400 Oostende.Company details
What does FARMACYZE do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of FARMACYZE?
The legal form of FARMACYZE is Private limited company (BV).
When was FARMACYZE founded?
FARMACYZE was founded on 21-08-2024.
Is FARMACYZE still active?
Yes, FARMACYZE is an active enterprise in the KBO register.
What is the turnover of FARMACYZE?
The turnover in financial year 2025 is ≈ €210,000. This figure is estimated from the gross margin of €42,761 and 51 comparable companies (NACE 477). It probably lies between €110,000 and €370,000. In financial year 2024 turnover was €36,270.Financials
Is FARMACYZE profitable?
In financial year 2025, FARMACYZE made a profit of €33,612.
Where can I find the annual accounts of FARMACYZE?
FARMACYZE filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of FARMACYZE due?
FARMACYZE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.